J7677 HCPCS code: Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram
J7677 is the HCPCS Level II code for revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram. In 2024 Medicare paid an average of $0.15 per service for J7677 across 826 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 175 per day on outpatient hospital claims. Medicare volume rose 123% from 2022 to 2024 (370 to 826 services). In 2024, 4,532 suppliers billed Medicare for J7677 (purchases), serving 29,205 beneficiaries; Texas, California, Florida accounted for 20% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | D1G — Drugs administered through DME |
| Added | 2019-07-01 |
| Last action effective | 2019-07-01 |
Who bills J7677 (2024)
| Measure | Value |
|---|---|
| Suppliers billing rentals | — |
| Suppliers billing purchases | 4,532 |
| Referring clinicians | 10,496 |
| Medicare beneficiaries | 29,205 |
| States with claims | 52 |
| Share of services in top 3 states (Texas, California, Florida) | 20% |
| Year | Suppliers | Beneficiaries |
|---|---|---|
| 2022 | 4,483 | 27,005 |
| 2023 | 4,719 | 28,751 |
| 2024 | 4,532 | 29,205 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J7677, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 370 | 18 | $0.18 | $0.14 |
| 2023 | 196 | 20 | $0.18 | $0.14 |
| 2024 | 826 | 44 | $0.18 | $0.15 |
States with the most J7677 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Illinois | 43 | $0.14 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 175 | Prescribing Information |
| practitioner claims | 175 | Prescribing Information |
Medicare policy articles for this code
- A52466: Nebulizers - Policy Article (CGS Administrators, LLC (DME MAC) Noridian Healthcare Solutions, LLC (DME MAC)) — mentions this code in its coding guidance
Covered diagnoses (215 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| A15.0 | Tuberculosis of lung | 1 |
| A22.1 | Pulmonary anthrax | 1 |
| A37.01 | Whooping cough due to Bordetella pertussis with pneumonia | 1 |
| A37.11 | Whooping cough due to Bordetella parapertussis with pneumonia | 1 |
| A37.81 | Whooping cough due to other Bordetella species with pneumonia | 1 |
| A37.91 | Whooping cough, unspecified species with pneumonia | 1 |
| A48.1 | Legionnaires' disease | 1 |
| B20 | Human immunodeficiency virus [HIV] disease | 1 |
| B25.0 | Cytomegaloviral pneumonitis | 1 |
| B44.0 | Invasive pulmonary aspergillosis | 1 |
Showing 10 of 215. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for J7677
- 2019-07-01: J7677 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J7677?
J7677 is the HCPCS Level II code for revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram. Short descriptor: "Revefenacin inh non-com 1mcg".
How much does Medicare pay for J7677?
In 2024, the average Medicare payment was $0.15 per service (average allowed $0.18).
Does Medicare cover J7677?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for J7677?
Medicare policy articles that cite J7677 list 215 covered ICD-10-CM diagnosis codes across 1 article. The most cited include A15.0 (Tuberculosis of lung), A22.1 (Pulmonary anthrax), A37.01 (Whooping cough due to Bordetella pertussis with pneumonia). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J7677 can be billed per day?
175 on outpatient hospital claims; 175 on practitioner claims (NCCI medically unlikely edits).
Related J76 codes
- J7601 — Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg
- J7604 — Acetylcysteine, inhalation solution, compounded product, administered through dme, unit dose form, per gram
- J7605 — Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 micrograms
- J7606 — Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms
- J7607 — Levalbuterol, inhalation solution, compounded product, administered through dme, concentrated form, 0.5 mg
- J7608 — Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram
- J7609 — Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mg
- J7610 — Albuterol, inhalation solution, compounded product, administered through dme, concentrated form, 1 mg
- J7611 — Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg
- J7612 — Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg
- J7613 — Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg
- J7614 — Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J7677
- Watch J7677 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J7677
Sources: CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.